Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-IL-17A Monoclonal Antibody

Secukinumab

Brand names: Cosentyx

Secukinumab is a fully human monoclonal antibody targeting interleukin-17A, used for moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds and neutralises interleukin-17A, a key pro-inflammatory cytokine driving keratinocyte activation and inflammation in psoriasis and related conditions.

Prescribing in practice

  • Screen for active and latent tuberculosis and active infection before starting, as IL-17 inhibition increases infection risk.
  • Use with caution in patients with inflammatory bowel disease, which may be triggered or exacerbated.
  • Increased susceptibility to mucocutaneous candidiasis should be anticipated and managed.

Monitoring

No mandatory routine bloods are required, but monitor clinically for infection, new or worsening inflammatory bowel disease and treatment response.

Counselling the patient

  • Report signs of infection or new or worsening bowel symptoms such as diarrhoea or abdominal pain.
  • Patients can be trained to self-inject using the pre-filled device.
  • Avoid live vaccines while on treatment.

Evidence & guidelines

NICE recommends secukinumab as an option for severe plaque psoriasis, with efficacy shown in the ERASURE and FIXTURE trials.

Reference: NICE TA350; CLEAR Trial; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways